The Law Offices of Frank R. Cruz Announces Investigation of General Motors Company (GM) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of General Motors Company (“GM” or the “Company”) (NYSE:... Read more.
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Updated results highlight the range of differentiated research platforms across BMS’ multiple myeloma pipeline, including cell therapy and protein degradation... Read more.
DNP Develops Photomask Process for 3nm EUV Lithography
– Responding to semiconductor market needs where circuit line widths are becoming increasingly finer – TOKYO–(BUSINESS WIRE)–Dai Nippon Printing... Read more.
The Law Offices of Frank R. Cruz Announces Investigation of National Instruments Corporation (NATI) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of National Instruments Corporation (“National Instruments”... Read more.
Sunnova Reiterates Commitment to Project Hestia, Ethical Business Practices, and Customer Service
HOUSTON–(BUSINESS WIRE)–Sunnova Energy International Inc. (“Sunnova”) (NYSE: NOVA), a leading adaptive energy services company, today reiterated... Read more.
The Law Offices of Frank R. Cruz Announces Investigation of LivePerson, Inc. (LPSN) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of LivePerson, Inc. (“LivePerson” or the “Company”) (NASDAQ:... Read more.
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
– At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with... Read more.
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of care The as-treated population... Read more.
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with... Read more.
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
– Longer-term follow-up data demonstrate consistent and durable response to treatment – BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated... Read more.